USX:ABAX - Abaxis Inc. (USD 83) Abaxis Inc.
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist
   


Yahoo Finance
Note: This stock seems to be inactive

USD 83.0    -0.090 (-0.11%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

31 Jul 2018


Overview

31 Jul 2018

Day Change: -0.090 (-0.11%)

52 Wk Range: 43.66 - 83.98

Day's Range: 83.0 - 83.24

Last Volume: 354,744

Current Yield: 0.77%

Projected Yield: 0%

Open: USD 83.11

31 Jul 2019

Metric ABAX S.Median
Beta NA 0.72
VaR NA 16.91
E.Shortfall NA 23.3
Liquidity NA 71.96K

Fundamental

31 Jul 2018

PE: 70.656

Market Cap: 1.9B

Price Over Book: 6.606

Price Over Sales: 7.85

Return On Assets: 8%

Return On Equity: 9.3%

Price Over NAV: [Friends Only]

General

CEO: Clinton H. Severson

Headquarters: UNION CITY

Employees: 549

Sector: Health Technology

Industry: Medical Specialties

Useful Links
Homepage

Description

Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo Xpress chemistry analyzers with blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; VetScan HM5; and VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results. Further, it provides VetScan rapid tests for the detection of various diseases. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.